Protalix Revenue Miss Overshadowed By Milestone-Backed 2026 Guidance [Seeking Alpha]
Protalix BioTherapeutics, Inc. (DE) (PLX)
NASDAQ:AMEX Investor Relations:
phx.corporate-ir.net/phoenix.zhtml?c=101161&p=irol-irhome
Company Research
Source: Seeking Alpha
PLX's growth thesis centers on Elfabrio's EU approval and once-every-4-weeks dosing, offering a clear competitive and patient adherence advantage. Chiesi's contribution is expected to exceed 50% revenue growth in 2026, improving margin mix and earnings predictability despite near-term volatility. Valuation remains discounted at 1.9x EV/sales and 9.9x forward P/E, reflecting market skepticism on durability, partner reliance, and pipeline risk. Piyaphorn Promnonsri/E+ via Getty Images Thesis Protalix BioTherapeutics, Inc. ( PLX ) for FY25 reported a lot weaker-than-expected results. GAAP EPS was a loss of $0.08, missing the consensus by about $0.07, with revenue reaching $52.7 million. Revenue was down just 1% year over year but missed The once-every-4-weeks dosing approval in Europe differentiates Elfabrio, reduces patient burden, and is expected to drive new patient starts and switches from competitors. Risks include lack of a clear U.S. dosing approval timeline, partne
Show less
Read more
Impact Snapshot
Event Time:
PLX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PLX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PLX alerts
High impacting Protalix BioTherapeutics, Inc. (DE) news events
Weekly update
A roundup of the hottest topics
PLX
News
- Protalix BioTherapeutics (PLX) had its "buy" rating reaffirmed by HC Wainwright. They now have a $12.00 price target on the stock.MarketBeat
- Protalix BioTherapeutics Inc (PLX) Q4 2025 Earnings Call Highlights: Strategic Advances and ... [Yahoo! Finance]Yahoo! Finance
- Protalix BioTherapeutics advances Fabry disease and gout programs during 2025 [Yahoo! Finance]Yahoo! Finance
- Protalix BioTherapeutics Reports Fiscal Year 2025 Financial and Business ResultsPR Newswire
- Protalix BioTherapeutics FY Earnings Preview [Seeking Alpha]Seeking Alpha
PLX
Earnings
- 3/18/26 - Miss
PLX
Analyst Actions
- 3/19/26 - HC Wainwright
PLX
Sec Filings
- 3/18/26 - Form 10-K
- 3/18/26 - Form 8-K
- 3/9/26 - Form 8-K
- PLX's page on the SEC website